X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://ir.horizontherapeutics.com/news-releases/news-release-details/upliznar-inebilizumab-cdon-approved-brazil-treatment
https://www.ema.europa.eu/en/documents/overview/uplizna-epar-medicine-overview_en.pdf
https://ir.horizontherapeutics.com/news-releases/news-release-details/new-analysis-upliznar-inebilizumab-cdon-phase-3-trial-data
https://www.ema.europa.eu/en/documents/overview/uplizna-epar-medicine-overview_en.pdf
https://finance.yahoo.com/news/analysis-uplizna-inebilizumab-cdon-neuromyelitis-123000441.html
https://www.businesswire.com/news/home/20210324005304/en/UPLIZNA%C2%AE-inebilizumab-cdon-Approved-by-Japanese-Ministry-of-Health-Labour-and-Welfare-for-the-Prevention-of-Relapses-of-Neuromyelitis-Optica-Spectrum-Disorder-NMOSD
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761142
https://www.prnewswire.com/news-releases/pantherx-chosen-as-exclusive-rare-pharmacy-partner-by-viela-bio-inc-for-uplizna-inebilizumab-cdon-for-adult-patients-with-aqp4-neuromyelitis-optica-spectrum-disorder-nmosd-301075247.html
https://www.prnewswire.com/news-releases/fda-approves-new-therapy-for-rare-disease-affecting-optic-nerve-spinal-cord-301074820.html
https://www.globenewswire.com/news-release/2020/06/11/2047190/0/en/Viela-Bio-Announces-U-S-FDA-Approval-of-UPLIZNA-inebilizumab-cdon-for-the-Treatment-of-Neuromyelitis-Optica-Spectrum-Disorder-NMOSD.html
Market Place
Share 
